GL701 (prasterone) significantly reduces lu...( s data from two Phase III clinical tria...),Health

The GL701 used in this Phase III study in Taiwan contains the same amount of active ingredient (prasterone) as in the GL701 used to support Genelabs Technologies, Inc. studies in the U.S., but in a slightly different formulation.

Approximately 200,000 people in the United States and more than one million worldwide have lupus, according to U.S. government and private sector statistics. Lupus primarily affects women, many of whom experience the initial onset in their late teens and early twenties.

In lupus, the body develops antibodies that react against a person's normal tissue, which can lead to inflammation, arthritis pain, tissue injury and major organ damage. The disease is characterized by flares of disease activity interspersed with periods of improvement or remission. Lupus can be mild but also can cause significant and potentially severe damage to organs such as the lungs, heart, kidney, and brain. Common signs and symptoms of disease that lupus sufferers experience - severe fatigue, arthritis, facial rash, fever, seizures, headache, muscle weakness, memory loss, hair loss, and photosensitivity - can lead to a poor quality of life.

'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000